CR11146A - Antagonistas piridil piperidina del receptor de orexina - Google Patents

Antagonistas piridil piperidina del receptor de orexina

Info

Publication number
CR11146A
CR11146A CR11146A CR11146A CR11146A CR 11146 A CR11146 A CR 11146A CR 11146 A CR11146 A CR 11146A CR 11146 A CR11146 A CR 11146A CR 11146 A CR11146 A CR 11146A
Authority
CR
Costa Rica
Prior art keywords
orexina
antigonistas
piperidina
piridil
receiver
Prior art date
Application number
CR11146A
Other languages
English (en)
Inventor
Michael J Breslin
Paul J Coleman
Christopher D Cox
John D Schreier
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CR11146A publication Critical patent/CR11146A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invencion se refiere a compuestos de piridil piperidina que son antagonistas de los receptores de orexina y que son utiles en el tratamiento o prevencion de trastornos y enfermedades neurologicas y psiquiatricas en las que estan implicados los receptores de orexina. La invencion tambien se refiere a composiciones farmaceuticas que comprenden estos compuestos y al uso de estos compuestos y composiciones en la prevencion o tratamiento de dichas enfermedades en las que estan implicados los receptores de orexina.
CR11146A 2007-05-23 2009-12-04 Antagonistas piridil piperidina del receptor de orexina CR11146A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93145807P 2007-05-23 2007-05-23

Publications (1)

Publication Number Publication Date
CR11146A true CR11146A (es) 2010-03-01

Family

ID=39708485

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11146A CR11146A (es) 2007-05-23 2009-12-04 Antagonistas piridil piperidina del receptor de orexina

Country Status (34)

Country Link
US (2) US8242121B2 (es)
EP (1) EP2152690B1 (es)
JP (2) JP4881476B2 (es)
KR (1) KR101480279B1 (es)
CN (1) CN101679366B (es)
AT (1) ATE540944T1 (es)
AU (1) AU2008257411B2 (es)
BR (1) BRPI0811842A2 (es)
CA (1) CA2687321C (es)
CO (1) CO6251266A2 (es)
CR (1) CR11146A (es)
CY (1) CY1112969T1 (es)
DK (1) DK2152690T3 (es)
DO (1) DOP2009000263A (es)
EC (1) ECSP099749A (es)
ES (1) ES2379744T3 (es)
GT (1) GT200900300A (es)
HK (1) HK1134084A1 (es)
HR (1) HRP20120240T1 (es)
IL (1) IL201790A0 (es)
MA (1) MA31451B1 (es)
MX (1) MX2009012579A (es)
MY (1) MY148544A (es)
NI (1) NI200900193A (es)
NZ (1) NZ580887A (es)
PL (1) PL2152690T3 (es)
PT (1) PT2152690E (es)
RS (1) RS52200B (es)
RU (1) RU2470021C2 (es)
SI (1) SI2152690T1 (es)
SV (1) SV2009003417A (es)
UA (1) UA99620C2 (es)
WO (1) WO2008147518A1 (es)
ZA (1) ZA200907495B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200823227A (en) * 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
PT2152690E (pt) 2007-05-23 2012-03-30 Merck Sharp & Dohme Antagonistas piridil piperidina de receptor de orexina
NZ583487A (en) * 2007-07-27 2011-09-30 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
CA2699328A1 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
CA2713184A1 (en) * 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) * 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
EP2318367B1 (en) * 2008-04-30 2013-03-20 Actelion Pharmaceuticals Ltd. Piperidine and pyrrolidine compounds
MX2010012631A (es) * 2008-05-22 2010-12-14 Merck Sharp & Dohme Procedimiento para la preparacion de un antagonista del receptor orexina.
US8546576B2 (en) * 2008-06-06 2013-10-01 Sk Biopharmaceuticals Co., Ltd. 3 or 4-substituted piperidine compounds
AU2009307916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
WO2010048014A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
EP2348846B1 (en) * 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
CA2739916A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010048010A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
WO2011023578A1 (en) * 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
EP2632253B1 (en) * 2010-10-29 2016-04-06 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
EP2484674A1 (en) 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
WO2012114252A1 (en) * 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
JPWO2013005755A1 (ja) 2011-07-05 2015-02-23 大正製薬株式会社 メチルピペリジン誘導体
EP3189840B1 (en) 2011-07-28 2021-05-19 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013059163A1 (en) * 2011-10-21 2013-04-25 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
ITMI20112329A1 (it) 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
JP6346862B2 (ja) * 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
ES2733750T3 (es) * 2012-02-17 2019-12-02 Eisai R&D Man Co Ltd Métodos y compuestos útiles en la síntesis de antagonistas del receptor de orexina-2
ITMI20120322A1 (it) 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
LT2862860T (lt) * 2012-06-15 2017-03-10 Taisho Pharmaceutical Co., Ltd. 1,3-oksazolidino arba 1,3-oksazinano junginiai kaip oreksino receptoriaus antagonistai
WO2014081617A1 (en) * 2012-11-20 2014-05-30 Merck Sharp & Dohme Corp. Substituted pyridone derivatives as pde10 inhibitors
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
WO2014099696A1 (en) * 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-ester orexin receptor antagonists
US9765057B2 (en) 2012-12-20 2017-09-19 Merck Sharp & Dohme Corp. 3-ester-4 substituted orexin receptor antagonists
US9643955B2 (en) * 2012-12-20 2017-05-09 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists
EP2945630A4 (en) 2013-01-16 2016-06-22 Merck Sharp & Dohme ANTAGONISTS OF OREXIN RECEPTORS OF THE TYPE OF 4-FLUOROPIPERIDINE COMPOUNDS
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
EP2964226A4 (en) 2013-03-08 2016-08-10 Merck Sharp & Dohme 2-pyridyloxy-4-ESTER-orexin receptor antagonists
US20160068514A1 (en) * 2013-04-23 2016-03-10 Merck Sharp & Dohme Corp. Halo and trifluoromethyl substituted orexin receptor antagonists
US9725434B2 (en) * 2013-04-23 2017-08-08 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
WO2015018029A1 (en) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
WO2015018027A1 (en) 2013-08-08 2015-02-12 Merck Sharp & Dohme Corp. Thiazole orexin receptor antagonists
WO2015095441A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-amino-3-ester-pyridyl orexin receptor antagonists
SG10201900536TA (en) * 2014-03-06 2019-02-27 Shanghai Haiyan Pharmaceutical Tech Co Ltd Piperidine derivatives as orexin receptor antagonist
CA2944049A1 (en) * 2014-03-27 2015-10-01 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
TW201613902A (en) 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
WO2016065584A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine oxadiazole and thiadiazole orexin receptor antagonists
WO2016065586A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole, triazole and tetrazole orexin receptor antagonists
WO2016065587A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Pyrazole orexin receptor antagonists
WO2016065585A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Piperidine isoxazole and isothiazole orexin receptor antagonists
WO2016065583A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Oxazole orexin receptor antagonists
US10000499B2 (en) 2014-11-26 2018-06-19 Merck Sharp & Dohme Corp. Methyl diazepane orexin receptor antagonists
WO2016085783A1 (en) 2014-11-26 2016-06-02 Merck Sharp & Dohme Corp. Bridged diazepane orexin receptor antagonists
WO2016086358A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Hydroxymethyl piperidine orexin receptor antagonists
WO2016086357A1 (en) 2014-12-02 2016-06-09 Merck Sharp & Dohme Corp. Methyl oxazole orexin receptor antagonists
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2016095204A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor antagonists
US10011595B2 (en) 2014-12-19 2018-07-03 Merck Sharp & Dohme Corp. Ethyldiamine orexin receptor antagonists
US9987255B2 (en) 2014-12-19 2018-06-05 Merck Sharp & Dohme Corp. 5,5-bicyclic oxazole orexin receptor antagonists
WO2016095205A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
WO2016101118A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Amidoethyl azole orexin receptor antagonists
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
AU2016295693B2 (en) 2015-07-17 2020-05-21 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
DK3336088T3 (da) * 2015-08-14 2021-06-28 Shanghai Haiyan Pharmaceutical Tech Co Ltd Krystalform af orexinreceptorantagonistforbindelse, og fremgangsmåde til fremstilling og anvendelse af denne
WO2017035232A1 (en) * 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN108513615B (zh) 2015-09-30 2022-03-08 鸟石生物公司 结合人大麻素1(cb1)受体的抗体
RS63471B1 (sr) 2016-02-12 2022-08-31 Astrazeneca Ab Halo-supstituisani piperidini kao modulatori receptora oreksina
EP3454857A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
PT3551619T (pt) 2016-12-11 2024-06-14 Zevra Therapeutics Inc Composições compreendendo profármacos de metilfenidato, processos de preparação e utilização dos mesmos
WO2020004537A1 (ja) * 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
ES2196806T3 (es) 1998-05-08 2003-12-16 Smithkline Beecham Plc Derivados de fenilurea y de feniltiourea.
EP1150977B1 (en) 1999-02-12 2004-08-25 SmithKline Beecham plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
US6596730B1 (en) 1999-02-12 2003-07-22 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives
KR20020080378A (ko) 2000-01-20 2002-10-23 에자이 가부시키가이샤 신규 피페리딘 화합물 및 그의 의약
DE60108236T2 (de) 2000-03-14 2005-12-22 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate
AU779266B2 (en) 2000-05-11 2005-01-13 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
ES2234929T3 (es) 2000-11-28 2005-07-01 Smithkline Beecham Plc Derivados de morfolina como antagonistas de los receptores de orexina.
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体
EP1385845B1 (en) 2001-05-05 2008-01-09 Smithkline Beecham Plc N-aroyl cyclic amines
EP1705179A1 (en) 2001-06-28 2006-09-27 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130388D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
RU2294927C2 (ru) * 2002-05-29 2007-03-10 Танабе Сейяку Ко., Лтд. Производные пиперидина, способы их получения, фармацевтическая композиция на их основе, их применение и способ лечения
TWI283241B (en) 2002-05-29 2007-07-01 Tanabe Seiyaku Co Novel piperidine compound
ITMI20021273A1 (it) * 2002-06-11 2003-12-11 Milano Politecnico Sistema e metodo per la rilevazione automatica della limitazione del flusso espiratorio
US7067519B2 (en) 2002-07-09 2006-06-27 Hamed Aissaoui 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
EP1539747B1 (en) 2002-09-18 2006-11-02 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
EP1551823A1 (en) 2002-10-08 2005-07-13 Merck Frosst Canada Inc. 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
WO2004033418A2 (en) 2002-10-11 2004-04-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
AU2003299648A1 (en) 2002-12-12 2004-06-30 Janssen Pharmaceutica, N.V. Substituted 4-phenyl-(1,3)-dioxanes
CL2004000553A1 (es) 2003-03-20 2005-02-04 Actelion Pharmaceuticals Ltd Uso de compuestos derivados de guanidina como antagonistas del receptor de neuropeptido ff; compuestos derivados de guanidina; procedimientos de preparacion; y composicion farmaceutica que los comprende.
ATE435210T1 (de) 2003-03-26 2009-07-15 Actelion Pharmaceuticals Ltd Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CN1780820A (zh) 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为阿立新受体拮抗剂的喹喔啉－3－酮衍生物
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
DE102004062544A1 (de) 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
JP2008538361A (ja) 2005-04-12 2008-10-23 メルク エンド カムパニー インコーポレーテッド アミドプロポキシフェニルオレキシン受容体アンタゴニスト
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
JP2008542276A (ja) 2005-05-23 2008-11-27 メルク エンド カムパニー インコーポレーテッド プロリンビスアミドオレキシン受容体アンタゴニスト
JP2009503106A (ja) 2005-08-04 2009-01-29 メルク エンド カムパニー インコーポレーテッド アミノエタンスルホンアミドオレキシン受容体アンタゴニスト
WO2007025069A2 (en) 2005-08-26 2007-03-01 Merck & Co., Inc. Diazaspirodecane orexin receptor antagonists
EP1954276A2 (en) 2005-11-22 2008-08-13 Merck & Co., Inc. Indole orexin receptor antagonists
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
EP2001485B1 (en) 2006-03-29 2015-09-09 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
JP2009533419A (ja) 2006-04-11 2009-09-17 アクテリオン ファーマシューティカルズ リミテッド 新規スルホンアミド化合物
CA2647077A1 (en) 2006-04-26 2007-11-01 Actelion Pharmaceuticals Ltd Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
CA2657552A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Substituted diazepan orexin receptor antagonists
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
AU2007272795A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
PL2069332T3 (pl) 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Związki azetydynowe jako antagoniści receptorów oreksynowych
CN101511833A (zh) 2006-08-28 2009-08-19 埃科特莱茵药品有限公司 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物
TW200823227A (en) 2006-09-29 2008-06-01 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
PT2152690E (pt) 2007-05-23 2012-03-30 Merck Sharp & Dohme Antagonistas piridil piperidina de receptor de orexina
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
MX2010012631A (es) 2008-05-22 2010-12-14 Merck Sharp & Dohme Procedimiento para la preparacion de un antagonista del receptor orexina.
WO2010048010A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
EP2348846B1 (en) 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
WO2010048014A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
AU2009307916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
WO2011023578A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder

Also Published As

Publication number Publication date
RU2470021C2 (ru) 2012-12-20
EP2152690A1 (en) 2010-02-17
BRPI0811842A2 (pt) 2014-11-18
NI200900193A (es) 2011-02-11
KR101480279B1 (ko) 2015-01-09
HRP20120240T1 (hr) 2012-04-30
SI2152690T1 (sl) 2012-05-31
CA2687321C (en) 2013-10-08
US8242121B2 (en) 2012-08-14
UA99620C2 (en) 2012-09-10
KR20100019984A (ko) 2010-02-19
CA2687321A1 (en) 2008-12-04
ZA200907495B (en) 2010-08-25
JP5639564B2 (ja) 2014-12-10
DOP2009000263A (es) 2009-12-31
AU2008257411B2 (en) 2012-04-26
ATE540944T1 (de) 2012-01-15
RU2009147733A (ru) 2011-06-27
JP4881476B2 (ja) 2012-02-22
PT2152690E (pt) 2012-03-30
JP2010528011A (ja) 2010-08-19
US20120295921A1 (en) 2012-11-22
US8569311B2 (en) 2013-10-29
ES2379744T3 (es) 2012-05-03
DK2152690T3 (da) 2012-05-07
ECSP099749A (es) 2009-12-28
CN101679366A (zh) 2010-03-24
JP2012051924A (ja) 2012-03-15
SV2009003417A (es) 2010-04-13
RS52200B (en) 2012-10-31
CO6251266A2 (es) 2011-02-21
IL201790A0 (en) 2010-06-16
CN101679366B (zh) 2013-08-07
EP2152690B1 (en) 2012-01-11
HK1134084A1 (en) 2010-04-16
MY148544A (en) 2013-04-30
MA31451B1 (fr) 2010-06-01
MX2009012579A (es) 2009-12-08
US20100168134A1 (en) 2010-07-01
CY1112969T1 (el) 2016-04-13
GT200900300A (es) 2011-06-23
PL2152690T3 (pl) 2012-06-29
AU2008257411A1 (en) 2008-12-04
WO2008147518A1 (en) 2008-12-04
NZ580887A (en) 2012-03-30

Similar Documents

Publication Publication Date Title
DOP2009000263A (es) Antagonistas piridil piperdina del receptor de orexina
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
DK2049529T3 (da) Substituerede diazepan-orexin-receptor- antagonister
MX2009005712A (es) Antagonistas de receptor de orexina de diazepam sustituido.
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
UA100974C2 (ru) Соединения замещенных диазепанов как антагонисты орексиновых рецепторов
WO2007126935A3 (en) Diazepan orexin receptor antagonists
WO2007061763A3 (en) Indole orexin receptor antagonists
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2008008517A3 (en) Bridged diazepan orexin receptor antagonists
WO2007025069A3 (en) Diazaspirodecane orexin receptor antagonists
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
MA32975B1 (fr) Antagonistes de c5ar
WO2007019234A3 (en) Aminoethane sulfonamide orexin receptor antagonists